Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04AIB
|
|||
| Former ID |
DIB014250
|
|||
| Drug Name |
AZD1772//RDX5791
|
|||
| Indication | Chronic kidney disease [ICD-11: GB61; ICD-10: N18, N18.9] | Phase 2 | [1] | |
| Company |
Ardelyx; astrazeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium/hydrogen exchanger 3 (SLC9A3) | Target Info | Modulator | [2] |
| KEGG Pathway | Proximal tubule bicarbonate reclamation | |||
| Protein digestion and absorption | ||||
| Bile secretion | ||||
| Mineral absorption | ||||
| Pathway Interaction Database | Endothelins | |||
| RhoA signaling pathway | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Ardelyx. | |||
| REF 2 | RDX5791, a First-in-Class Minimally Systemic NHE3 Inhibitor in Clinical Development for CIC and IBS-C, Increases Intestinal Sodium Leading to Enhanced Intestinal Fluid Volume and Transit. Gastroenterology. 2011;140(suppl 1):S99. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.